Post by Agilent Technologies

Peptide therapeutics are scaling faster than ever. GLP-1 programs are moving from innovation to industrial reality and analytical rigor is now a differentiator, not a checkbox. As the need for API development and CDMO manufacturing rapidly grow, labs need workflows that scale with confidence, from development through QC. Explore our latest resources built to power your GLP-1 development with reproducibility, speed, and regulatory alignment. Access here: https://lnkd.in/dEfGWEMq #Peptidetherapeutics #GLP1 #Biopharma #Agilent